C M Bollard

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi request reprint Gene-marking studies of hematopoietic cells
    C M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Int J Hematol 73:14-22. 2001
  2. ncbi request reprint The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    J Immunother 27:317-27. 2004
  3. ncbi request reprint Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Clin Lymphoma Myeloma 6:342-7. 2006
  4. ncbi request reprint In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Leuk Lymphoma 47:837-42. 2006
  5. pmc Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 110:2838-45. 2007
  6. pmc Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease
    Catherine M Bollard
    Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    J Exp Med 200:1623-33. 2004
  7. ncbi request reprint Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation
    G D Myers
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
    Bone Marrow Transplant 39:677-86. 2007
  8. ncbi request reprint T cell therapies
    S Gottschalk
    Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3 3320, 77030 Houston, USA
    Ernst Schering Found Symp Proc . 2006
  9. ncbi request reprint Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)
    G D Myers
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, 77030, USA
    Bone Marrow Transplant 36:1001-8. 2005
  10. doi request reprint Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine
    Nabil Ahmed
    Center for Cell and Gene Therapy, Texas Children s Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1298-304. 2008

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Gene-marking studies of hematopoietic cells
    C M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Int J Hematol 73:14-22. 2001
    ..With continuing advances in gene-marking technology, the value of the information provided by these studies increases, thereby ensuring their continued relevance to the field of gene transfer...
  2. ncbi request reprint The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    J Immunother 27:317-27. 2004
    ..This approach is being used in a current clinical trial...
  3. ncbi request reprint Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Clin Lymphoma Myeloma 6:342-7. 2006
  4. ncbi request reprint In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Leuk Lymphoma 47:837-42. 2006
    ....
  5. pmc Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 110:2838-45. 2007
    ..This study is registered at http://www.cancer.gov/clinicaltrials (protocol IDs: BCM-H-9936, NCT00062868, NCT00070226)...
  6. pmc Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease
    Catherine M Bollard
    Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    J Exp Med 200:1623-33. 2004
    ..One additional patient had a partial response, and five had stable disease. The performance and fate of these human tumor antigen-specific T cells in vivo suggests that they might be of value for the treatment of EBV+ Hodgkin lymphoma...
  7. ncbi request reprint Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation
    G D Myers
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
    Bone Marrow Transplant 39:677-86. 2007
    ..In conclusion, recipients of alternative donor transplants at our institution have significantly delayed adv-specific cellular immune recovery, which correlates to an increased risk of adv-associated morbidity and mortality...
  8. ncbi request reprint T cell therapies
    S Gottschalk
    Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3 3320, 77030 Houston, USA
    Ernst Schering Found Symp Proc . 2006
    ..Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens...
  9. ncbi request reprint Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)
    G D Myers
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, 77030, USA
    Bone Marrow Transplant 36:1001-8. 2005
    ..This work will help in identifying at-risk populations for our upcoming immunotherapy trial using adoptively transferred donor-derived adenovirus-specific cytotoxic T lymphocytes...
  10. doi request reprint Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine
    Nabil Ahmed
    Center for Cell and Gene Therapy, Texas Children s Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1298-304. 2008
    ..Thus, the regimen that we describe can be used with minimal toxicity to effectively overcome graft failure after myeloablative HSCT in children...
  11. ncbi request reprint T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients
    A M Leen
    Center for Cell and Gene Therapy, Department of Pediatrics Hem Onc, Baylor College of Medicine, 6621 Fannin St, MC3 3320 Houston, TX 77030, USA
    Ann N Y Acad Sci 1062:104-15. 2005
    ..Thus, we have characterized human T-cell responses to adenovirus in vitro and explored the potential of adoptive T-cell immunotherapy as a prophylactic or therapeutic strategy for adenovirus infections posttransplant...
  12. ncbi request reprint Gene therapy for paediatric leukaemia
    R F Rousseau
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
    Expert Opin Biol Ther 1:663-74. 2001
    ..With the continued scientific advancements in this field, gene therapy will almost certainly have a major impact on the treatment of paediatric leukaemia in the future...
  13. doi request reprint Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant
    G Weber
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Leukemia 27:1538-47. 2013
    ....
  14. ncbi request reprint Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma
    Karin C Straathof
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    J Immunol 175:4137-47. 2005
    ..These new LMP2 epitopes broaden the diversity of HLA alleles with available epitopes, and, in particular, those epitopes conserved between EBV strains provide valuable tools for immunotherapy and immune monitoring...
  15. ncbi request reprint Options for T-cell based therapies
    H E Heslop
    Center for Gene and Cell Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Vox Sang 87:230-4. 2004
  16. ncbi request reprint T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?
    A A Kennedy-Nasser
    Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street, Houston, TX 77030, USA
    Bone Marrow Transplant 40:93-104. 2007
    ..This review focuses on the T-cell strategies currently available to allay disease while minimizing toxicities in patients who have undergone HSCT...
  17. pmc Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution
    J A Shafer
    Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Leuk Lymphoma 51:664-70. 2010
    ..Our data show encouraging outcomes for patients with chemosensitive relapsed HL who receive hematopoietic stem cell transplant (HSCT) and support the value of the procedure even when the disease is chemoresistant...
  18. ncbi request reprint Immune therapy for EBV infections after hemopoietic stem-cell transplant
    H E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston TX 77030, USA
    Cytotherapy 4:433-4. 2002
  19. pmc Immunotherapy targeting EBV-expressing lymphoproliferative diseases
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    Best Pract Res Clin Haematol 21:405-20. 2008
    ..A number of strategies to genetically modify the infused T cells and modulate the host environment are under evaluation...
  20. pmc Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
    Chrystal U Louis
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 113:2442-50. 2009
    ..Lymphodepleting mAbs prior CTL transfer may represent an alternative to chemotherapy to enhance expansion of infused CTL. This study is registered at (http://www.clinialtrials.gov) as NCT00608257...
  21. pmc Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
    Helen E Heslop
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 115:925-35. 2010
    ....
  22. pmc Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
    Kenneth P Micklethwaite
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
    Blood 115:2695-703. 2010
    ..This approach may prove beneficial for patients with high-risk B-ALL who have recently received an HSC or CB transplant and are at risk of infection and relapse...
  23. ncbi request reprint Adoptive immunotherapy for posttransplantation viral infections
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 10:143-55. 2004
    ..The use of genetically modified T cells or the use of newer suicide genes may result in improved safety and efficacy...
  24. ncbi request reprint Immunotherapy for Epstein-Barr virus-associated cancers in children
    Karin C M Straathof
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Oncologist 8:83-98. 2003
    ..If these strategies to improve the therapeutic potential of immunotherapy for EBV-associated tumors prove successful, this type of treatment may be adapted to other tumors expressing known (viral) antigens...
  25. pmc Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
    Patrick J Hanley
    Department of Immunology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Center for Cell and Gene Therapy, Houston, TX 77030, USA
    Blood 114:1958-67. 2009
    ..This study is registered at www.clinicaltrials.gov as NCT00078533...
  26. ncbi request reprint Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12
    Aaron E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, 6621 Fannin Street, Houston, TX 77030, USA
    J Immunother 30:506-16. 2007
    ..Thus, T cells provide a platform for the generation of autologous APC that can be customized to express both antigens and therapeutic molecules for the induction of antigen-specific T cell immunity...
  27. ncbi request reprint Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes
    Karin C M Straathof
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, 1102 Bates St, Suite 1120, Houston, TX 77030, USA
    Blood 105:1898-904. 2005
    ..These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity...
  28. ncbi request reprint Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab
    R Lamba
    Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Bone Marrow Transplant 36:797-802. 2005
    ..However, in the majority of patients, infection is transient, and antiviral T cell reconstitution is rapid. Monitoring with CMV-specific CTLs may help identify the subset of patients at risk from recurrent infection or disease...
  29. pmc Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy
    Ann M Leen
    Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street, MC 3 3320, Houston, TX 77030, USA
    J Virol 82:546-54. 2008
    ....
  30. ncbi request reprint Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy
    Claudia Rossig
    Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street, Houston, TX 77030, USA
    Blood 99:2009-16. 2002
    ..They efficiently lyse both. EBV-specific T cells expressing chimeric antitumor receptors may represent a new source of effector cells that would persist and function long-term after their transfer to cancer patients...
  31. ncbi request reprint Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia
    Alana A Kennedy-Nasser
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 12:1277-84. 2006
    ..We conclude that, for children with SAA, AD transplantation is as effective as MSD transplantation. Further, compared with ATG, preparatory regimens containing Campath may be associated with a lower incidence of extensive, chronic GHVD...
  32. pmc Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation
    Ann M Leen
    Center for Cell and Gene Therapy and Departments of Pediatrics, Immunology, Medicine, and Virology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Houston, TX 77030, USA
    Blood 114:4283-92. 2009
    ..This trial was registered at www.clinicaltrials.gov as #NCT00590083...
  33. ncbi request reprint Adoptive immunotherapy for Hodgkin's lymphoma
    Alana A Kennedy-Nasser
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Int J Hematol 83:385-90. 2006
    ..In this article, we discuss the promise of Epstein-Barr virus-specific cytotoxic T-lymphocytes, the roles of cytokines, and other strategies for overcoming the immune-evasion mechanisms in Hodgkin's lymphoma...
  34. pmc Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma
    Jessica A Shafer
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:870-80. 2010
    ..This study suggests that chemoresistant HL SP cells can be targeted by the immune system, providing a rationale for combined chemotherapy and immunotherapy for the treatment of HL...
  35. ncbi request reprint A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells
    Hans Joachim Wagner
    Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Gene Ther 11:81-91. 2004
    ..Tumor-specific, Flexi-IL12-transduced EBV-specific CTL should have a functional advantage over unmodified CTL, particularly in the presence of the adverse Th2 cytokine environment produced by Hodgkin tumor cells...
  36. doi request reprint Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen
    Alana A Kennedy-Nasser
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1245-52. 2008
    ..For children undergoing stem cell transplantation (SCT) from alternative donors, alemtuzumab with a myeloablative conditioning regimen resulted in DFS comparable to MSD...
  37. ncbi request reprint Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes
    C Rossig
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Int J Cancer 94:228-36. 2001
    ....
  38. ncbi request reprint Adenoviral infections in hematopoietic stem cell transplantation
    Ann M Leen
    Center for Cell and Gene Therapy, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 12:243-51. 2006
    ..We discuss the advantages and limitations of T-cell therapy for the prophylaxis and treatment of adenovirus infection posttransplantation...
  39. ncbi request reprint Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity
    Catherine M Bollard
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 99:3179-87. 2002
    ..Tumor-specific CTLs expressing HATGF-betaRII-Deltacyt should have a selective functional and survival advantage over unmodified CTLs in the presence of TGF-beta-secreting tumors and may be of value in treatment of these diseases...
  40. ncbi request reprint Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals
    Ann M Leen
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Nat Med 12:1160-6. 2006
    ..Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host...
  41. ncbi request reprint Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor
    Kristine Lacuesta
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    J Immunother 29:250-60. 2006
    ..They may be of value for treating human cancers, which use TGFbeta as a powerful immune evasion mechanism...
  42. pmc Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy
    C R Y Cruz
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, USA
    Clin Exp Immunol 174:89-96. 2013
    ..Our findings that T cells in CGD have a robust aspergillus CD4(+) T cell response suggest that CD4(+) T cell-based immunotherapy for this disease is unlikely to be beneficial. ..
  43. pmc Pediatric Hodgkin lymphoma: are we over-scanning our patients?
    N Rathore
    Texas Children s Cancer Center and Department of Pediatrics, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
    Pediatr Hematol Oncol 29:415-23. 2012
    ....
  44. ncbi request reprint Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease
    Catherine M Bollard
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Acta Haematol 110:139-48. 2003
    ..The infusion of EBV-CTL has been demonstrated to be safe and effective in allogeneic HSCT recipients and their use post-SOT is being evaluated...
  45. pmc Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor
    Aaron E Foster
    Center for Cell and Gene Therapy, The Methodist Hospital and Texas Children s Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
    J Immunother 31:500-5. 2008
    ..TGF-beta-resistant CTL had a functional advantage over unmodified CTL in the presence of TGF-beta-secreting EBV-positive lymphoma, and had enhanced antitumor activity, supporting the potential value of this countermeasure...
  46. ncbi request reprint Adoptive T-cell transfer in cancer immunotherapy
    Siok Keen Tey
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Immunol Cell Biol 84:281-9. 2006
    ....
  47. ncbi request reprint Genetically engineered T-cells for adoptive immunotherapy
    Martin Pule
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Curr Opin Mol Ther 4:467-75. 2002
    ..New strategies to target T-cells to tumors and to genetically modify them to make them resistant to tumor evasion mechanisms are being evaluated in preclinical models...
  48. pmc Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging
    Xin Gao
    The Center for Bioengineering and Informatics, The Methodist Hospital and The Methodist Hospital Research Institute, Weill Medical College of Cornell University, Houston, TX 77030, USA
    Acad Radiol 17:479-88. 2010
    ..This study develops and validates a Longitudinal Image Navigation and Analysis (LINA) system for this quantitative imaging application...
  49. pmc Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells
    David Steiner
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Stem Cells 27:1932-40. 2009
    ..The results suggest that multipotent stem cells can be expanded ex vivo and can contribute meaningfully to long-term hematopoietic engraftment...
  50. doi request reprint Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cells
    William K Decker
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Immunother 31:157-65. 2008
    ..Empirically, the data suggest that DCs matured with these agents are deficient in the induction of type 1 T-helper responses. We further speculate that DCs matured by these methods might be suboptimal for the priming of naive responses...